昊天發展集團(00474.HK)附屬與Promethera Biosciences成立合營公司
格隆匯 7 月 14日丨昊天發展集團(00474.HK)發佈公告，2020年7月13日，公司附屬公司Aceso Life Science與Promethera Biosciences訂立合營協議，以成立合營公司，其將有獨家權利從事開發、商業化、銷售及分銷基於Promethera Biosciences知識產權項目在該等地區的應用及開發，用於治療肝病、自身免疫性疾病及多種癌症的細胞及生物療法。
合營公司成立後應分別由Aceso Life Science及Promethera Biosciences擁有60%及40%。根據合營協議，在知識產權注入協議的條款及條件規限下，Promethera Biosciences與合營公司將訂立知識產權注入協議，以向合營公司轉讓及授出相關知識產權項目的從屬許可。憑藉已出讓或獲許可的知識產權項目，合營公司將擁有於大中華及東南亞研究、開發、利用及╱或商業化相關知識產權項目的獨家權利。Promethera Biosciences已保留若干權利以製造及供應擴增“通用型”肝臟幹細胞療法，並將向合營公司提供持續技術支援以於該等地區開發及商業化該等產品。
成立合營公司後，Promethera Biosciences將促使伊藤忠商事株式會社及合營公司訂立更替及經修訂合作協議，據此，伊藤忠商事株式會社及合營公司將就若干知識產權項目的治療用途展開聯合研究，並在取得令人滿意的結果及按個別基準就商業條款進行磋商後，在該等產品於亞洲進行分銷、授權及銷售產品方面展開合作。
此外，公司已有條件同意認購，而Promethera Biosciences已有條件同意配發及發行本金額最多1000萬歐元(相當於約8760萬港元)的可換股債券，分兩批等額發行，須根據可換股債券認購及股東協議的條款以現金支付。
可換股債券(面值及應計利息)可於到期日前任何時間按轉換價值約2.103億歐元(相當於約18.421億港元)轉換為Promethera優先股。於可換股債券獲悉數轉換後，假設其股本並無變動(就完成第二批可換股債券所需進一步融資除外)，公司將持有Promethera Biosciences經發行Promethera轉換股份擴大的已發行股本約4.14%。
第一批可換股債券須待若干先決條件獲達成(或(如適用)獲豁免)後方告完成，有關先決條件包括集團與Promethera Biosciences成立合營公司。第二批可換股債券的完成須待第一批可換股債券完成及Promethera Biosciences已籌集不少於1000萬歐元的額外資金後方可作實，而以上各項將同時完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
